# PTHS catalysts: Pelthos Therapeutics Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pths/catalysts

> Pelthos Therapeutics Inc. (PTHS) has no upcoming catalysts in this calendar. The latest recorded is the Pelthos Therapeutics Inc. earnings report, November 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Pelthos Therapeutics Inc. |
| Ticker | PTHS (NYSE) |
| SEC CIK | 1919246 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/pths |

## Cash runway

Cash $17.7M as of 2026-09-30; quarterly burn $5.2M; about 10.3 months of runway at that rate (XBRL company facts, accession 0001919246-26-000135).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 5, 2024 | [ZELSUVMI (berdazimer) FDA approval](https://sec-api.dev/pdufa/berdazimer) | PTHS |  | completed, approved | "This IP portfolio provides material coverage for our platform technologies, licensed products and product candidates, in addition to ZELSUVMI, which was approved by the FDA on January 5, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/886163/000088616325000012/lgnd-20241231.htm)) |
| 2025 | [CC8464 trial start](https://sec-api.dev/pdufa/cc8464) | PTHS |  | scheduled | "We are currently working on the development of the Phase 2a POC plan and expect to launch the Phase 2a POC study in 2025 to assess the potential efficacy of CC8464 in EM and iSFN patients." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1919246/000175392624001883/g084536_10q.htm)) |
| August 18, 2025 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000175392625001353/g084926_ex99-1.htm)) |
| late 2025 | [Pelthos Therapeutics Inc. topline data readout](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | scheduled | "The Company expects to commence Phase II human proof of concept studies in Q2 2025, with a readout by the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000175392624001983/g084575_ex99-1.htm)) |
| Oct 2025 | [CC8464 FDA approval](https://sec-api.dev/pdufa/cc8464) | PTHS |  | completed, approved | "Late 2026 Pelthos Opportunity Acquired from BioFrontera in October 2025 FDA Approved in 2017 Exclusivity until 2032 1https://www.cdc.gov/group-a-strep/about/impetigo.html" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000094/g085077_ex99-1.htm)) |
| Oct 2025 | [Pelthos Therapeutics Inc. FDA approval](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed, approved | "Anticipated Commercial Launch: Q1 2027 Pelthos Opportunity Acquired from BioFrontera in October 2025 FDA Approved in 2017 Exclusivity until 2032 1https://www.cdc.gov/group-a-strep/about/impetigo.html" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/investmentdeck_202608xex.htm)) |
| Oct 2025 | [Xepi® (ozenoxacin) FDA approval](https://sec-api.dev/pdufa/ozenoxacin) | PTHS |  | completed, approved | "Anticipated Commercial Launch: Early 2027 Pelthos Opportunity Acquired from BioFrontera in October 2025 FDA Approved in 2017 Exclusivity until 2032 1https://www.cdc.gov/group-a-strep/about/impetigo.html" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000085/exhibit992.htm)) |
| November 13, 2025 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos" or the "Company"), today announced its financial results for the three and nine months ended September 30, 2025, which can be found at the Financial Results section of the Company's website at https://ir.pelthos.com/financial-info/financial-results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000175392625001766/g085015_ex99-1.htm)) |
| Dec 2025 | [CC8464 FDA approval](https://sec-api.dev/pdufa/cc8464) | PTHS |  | completed, approved | "Acquired from Hatchtech in December 2025 FDA Approved in 2020 Exclusivity until 2034 1https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000094/g085077_ex99-1.htm)) |
| Dec 2025 | [Pelthos Therapeutics Inc. FDA approval](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed, approved | "Anticipated Commercial Launch: Q3 2027 Pelthos Opportunity Acquired from Hatchtech in December 2025 FDA Approved in 2020 Exclusivity until 2034 1https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/investmentdeck_202608xex.htm)) |
| Dec 2025 | [Xepi® (ozenoxacin) FDA approval](https://sec-api.dev/pdufa/ozenoxacin) | PTHS |  | completed, approved | "Anticipated Commercial Launch: Mid-2027 Pelthos Opportunity Acquired from Hatchtech in December 2025 FDA Approved in 2020 Exclusivity until 2034 1https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000085/exhibit992.htm)) |
| March 19, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000014/pths-pressreleasex20250319.htm)) |
| May 14, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000071/pths-pressreleasex20250514.htm)) |
| August 13, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/pths-pressreleasex20260813.htm)) |
| November 12, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000134/pths-pressreleasex20261112.htm)) |

## Drugs

- [ZELSUVMI (berdazimer)](https://sec-api.dev/pdufa/berdazimer): 
- [CC8464](https://sec-api.dev/pdufa/cc8464): 
- [Xepi® (ozenoxacin)](https://sec-api.dev/pdufa/ozenoxacin): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pths/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PTHS catalysts: Pelthos Therapeutics Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pths/catalysts

```bibtex
@misc{secapidev_companies_pths_catalysts_20261116,
  title        = {PTHS catalysts: Pelthos Therapeutics Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pths/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pths_catalysts_20261116","title":"PTHS catalysts: Pelthos Therapeutics Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pths/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
